Vermillion Company Profile (NASDAQ:VRML)

About Vermillion (VRML)

Vermillion logoVermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic Substances
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VRML
  • CUSIP: N/A
Key Metrics:
  • Previous Close: $1.87
  • 50 Day Moving Average: $2.04
  • 200 Day Moving Average: $1.50
  • 52-Week Range: $0.76 - $2.85
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.54
  • P/E Growth: 0.00
  • Market Cap: $106.01M
  • Outstanding Shares: 56,089,000
  • Beta: 1.8
  • Net Margins: -778.21%
  • Return on Equity: -148.10%
  • Return on Assets: -111.43%
  • Debt-to-Equity Ratio: 0.27%
  • Current Ratio: 3.25%
  • Quick Ratio: 3.22%

Analyst Ratings

Consensus Ratings for Vermillion (NASDAQ:VRML) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.00 (5.82% upside)

Analysts' Ratings History for Vermillion (NASDAQ:VRML)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/23/2017Canaccord GenuitySet Price TargetBuy$2.00N/AView Rating Details
8/17/2015Roth CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 4/29/2015 forward)


Earnings History for Vermillion (NASDAQ:VRML)
Earnings by Quarter for Vermillion (NASDAQ:VRML)
Earnings History by Quarter for Vermillion (NASDAQ:VRML)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016Q316($0.06)($0.07)$0.62 millionViewN/AView Earnings Details
8/10/2016Q216($0.09)($0.07)$0.71 millionViewListenView Earnings Details
5/16/2016Q116($0.09)($0.09)$0.51 millionViewListenView Earnings Details
3/24/2016Q415($0.10)$1.20 million$0.36 millionViewListenView Earnings Details
11/12/2015Q315($0.10)($0.10)$0.57 million$0.33 millionViewListenView Earnings Details
8/13/2015Q215($0.08)($0.11)$1.50 million$535.00 millionViewListenView Earnings Details
5/11/2015Q115($0.10)($0.10)$0.81 million$0.95 millionViewListenView Earnings Details
3/25/2015Q414($0.08)($0.11)$1.59 million$1.57 millionViewListenView Earnings Details
11/14/2013Q3($0.10)$319.00 million$330.00 millionViewListenView Earnings Details
8/14/2013Q2 2013($0.11)$0.32 million$0.23 millionViewListenView Earnings Details
5/15/2013Q1 2013($0.15)($0.17)$0.30 million$0.33 millionViewListenView Earnings Details
11/12/2012Q312($0.21)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Vermillion (NASDAQ:VRML)
Current Year EPS Consensus Estimate: $-0.15 EPS
Next Year EPS Consensus Estimate: $-0.13 EPS


Dividend History for Vermillion (NASDAQ:VRML)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Vermillion (NASDAQ:VRML)
Insider Ownership Percentage: 2.19%
Institutional Ownership Percentage: 37.74%
Insider Trades by Quarter for Vermillion (NASDAQ:VRML)
Institutional Ownership by Quarter for Vermillion (NASDAQ:VRML)
Insider Trades by Quarter for Vermillion (NASDAQ:VRML)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/17/2017Larry N FeinbergInsiderBuy617,731$1.40$864,823.40View SEC Filing  
2/13/2017Eric SchoenSVPBuy3,347$1.40$4,685.80View SEC Filing  
2/13/2017Jack W SchulerMajor ShareholderBuy974,081$1.40$1,363,713.40View SEC Filing  
2/13/2017Valerie Barber PalmieriCEOBuy10,042$1.40$14,058.80View SEC Filing  
2/13/2017Veronica Gh JordanDirectorBuy6,695$1.40$9,373.00View SEC Filing  
1/28/2016Jack W SchulerMajor ShareholderBuy1,493$1.60$2,388.80View SEC Filing  
1/25/2016Jack W SchulerMajor ShareholderBuy3,700$1.57$5,809.00View SEC Filing  
1/21/2016Jack W SchulerMajor ShareholderBuy30,700$1.46$44,822.00View SEC Filing  
1/19/2016Jack W SchulerMajor ShareholderBuy57,749$1.45$83,736.05View SEC Filing  
1/15/2016Jack W SchulerMajor ShareholderBuy8,400$1.56$13,104.00View SEC Filing  
7/14/2015Larry N FeinbergInsiderBuy512,043$1.96$1,003,604.28View SEC Filing  
12/23/2014Jack W SchulerMajor ShareholderBuy1,288,339$1.44$1,855,208.16View SEC Filing  
12/23/2014Larry N FeinbergInsiderBuy972,222$1.44$1,399,999.68View SEC Filing  
12/19/2014Peter S RoddyDirectorBuy16,502$1.44$23,762.88View SEC Filing  
11/21/2014Valerie Barber PalmieriCOOBuy3,500$1.51$5,285.00View SEC Filing  
11/20/2014James T LafranceInsiderBuy27,907$1.44$40,186.08View SEC Filing  
11/20/2014Valerie Barber PalmieriCOOBuy30,000$1.44$43,200.00View SEC Filing  
11/19/2014James T LafranceInsiderBuy41,615$1.43$59,509.45View SEC Filing  
11/18/2014Eric SchoenCAOBuy5,000$1.42$7,100.00View SEC Filing  
11/20/2013William B CreechVPBuy2,000$2.33$4,660.00View SEC Filing  
6/11/2013William B CreechVPBuy10,000$3.18$31,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Vermillion (NASDAQ:VRML)
Latest Headlines for Vermillion (NASDAQ:VRML)
DateHeadline logoVermillion, Inc. (VRML) Short Interest Update - April 29 at 7:06 AM logoVermillion (VRML) Getting Favorable Media Coverage, Report Shows - April 28 at 1:38 PM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Vermillion, Inc. - (VRML) - April 28 at 10:34 AM logoVermillion to Report First Quarter 2017 Financial Results and Host Investor Conference Call on May 11 - April 26 at 5:09 PM logoSomewhat Negative News Coverage Extremely Likely to Affect Vermillion (VRML) Stock Price - April 25 at 3:30 PM logoVermillion (VRML) Getting Negative Media Coverage, Report Finds - April 19 at 8:23 AM logoAfter raising $2 million, Austin's Consortia Health tackles problems that might make some blush - April 15 at 7:00 PM logoETFs with exposure to Vermillion, Inc. : April 5, 2017 - April 7 at 1:24 PM logoVERMILLION, INC. Files SEC form 10-K, Annual Report - April 1 at 9:38 AM logoEdited Transcript of VRML earnings conference call or presentation 29-Mar-17 8:30pm GMT - March 30 at 8:18 AM logoASPiRA Labs Announces TriCare South Contract - March 30 at 8:18 AM logoQ4 2016 Vermillion Inc Earnings Release - Before Market Open - March 29 at 10:17 AM logoVermillion Announces Publication of Ovarian Cancer Symptoms Index Study - March 29 at 10:17 AM logoVermillion, Inc. (VRML) Scheduled to Post Quarterly Earnings on Wednesday - March 28 at 8:23 AM logoVermillion to Report Fourth Quarter and Full Year 2016 Financial Results and Host Investor Conference Call on March 29, 2017 - March 16 at 6:31 AM logoVERMILLION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - March 13 at 8:09 PM logoVermillion, Inc. (VRML) Sees Large Decline in Short Interest - March 13 at 8:23 AM logoASPiRA LABs Announces Provider Status with Medi-Cal Expanding OVA1® Access to Over 12 Million Beneficiaries - March 6 at 7:53 PM logoVERMILLION, INC. Files SEC form 8-K, Change in Directors or Principal Officers - March 4 at 3:56 AM logoASPiRA LABs Announces Contracted In-Network Agreement with Blue Cross Blue Shield of Michigan for OVA1® - March 2 at 1:23 AM logoVERMILLION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti - February 17 at 5:05 PM logoVermillion Announces Equity Financing of $5.6 Million - February 14 at 3:49 PM logoVERMILLION, INC. Files SEC form 8-K/A, Regulation FD Disclosure, Financial Statements and Exhibits - January 9 at 3:53 PM logoVermillion Announces Reimbursement Code Updates for Overa and OVA1 - January 9 at 3:53 PM logoVERMILLION, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - January 7 at 6:22 AM logo4:06 pm Vermillion & ASPiRA LABS announce receipt of formal FDA clarification regarding ovarian cancer screening alert - January 6 at 6:31 AM logoVermillion and ASPiRA LABS Announce Receipt of Formal FDA Clarification Regarding Ovarian Cancer Screening Alert - January 4 at 4:21 PM logoVermillion Announces Appointment of Chief Medical Officer - November 14 at 8:31 PM logoVermillion to Present Corporate Overview at the Canaccord Genuity Medical Technology and Diagnostic Forum - November 14 at 12:33 PM logoVermillion's (VRML) CEO Valerie Palmieri on Q3 2016 Results - Earnings Call Transcript - November 11 at 8:01 PM logoVermillion Reports Third Quarter 2016 Results - November 10 at 8:19 PM logoASPiRA LABS' OVA1 Technology Receives "Level B" Recommendation in the Latest ACOG Clinical Management Guidelines for the Management of Adnexal Masses - November 10 at 11:58 AM logoQ3 2016 Vermillion Inc Earnings Release - After Market Close - November 10 at 11:58 AM logoVermillion to Report Third Quarter 2016 Financial Results and Host Investor Conference Call on November 10th - October 27 at 9:55 AM logoVermillion CEO to Present at Women in Bio - New York - October 19 at 7:38 PM logo9:08 am Vermillion announces a contract agreement with CareFirst BlueCross BlueShield for their ovarian cancer risk assessment test, OVA1 - September 29 at 7:55 PM logoVermillion and ASPiRA LABs Applaud the FDA's Position on Ovarian Cancer Screening - September 9 at 7:37 PM logoVermillion, Inc. Kicks Off Ovarian Cancer Awareness Month by Ringing the NASDAQ Closing Bell with Olympic … - September 2 at 8:18 AM logoVermillion, Inc. Kicks Off Ovarian Cancer Awareness Month by Ringing the NASDAQ Closing Bell with Olympic Gymnast Shannon Miller, and NASCAR Driver Martin Truex, Jr.'s Life Partner, Sherry Pollex - September 1 at 8:00 PM logoVERMILLION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - August 10 at 11:25 AM logoVermillion to Present Corporate Overview at the Canaccord Genuity 36th Annual Growth Conference - August 8 at 8:22 PM logoVermillion to Report Second Quarter 2016 Financial Results and Host Investor Conference Call on August 10th - July 29 at 9:00 AM logoASPiRA LABS Announces Strategic Michigan Coverage for OVA1 - July 19 at 9:15 AM logoVERMILLION, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders - June 22 at 4:07 PM


Frequently Asked Questions for Vermillion (NASDAQ:VRML)

What is Vermillion's stock symbol?

Vermillion trades on the NASDAQ under the ticker symbol "VRML."

How were Vermillion's earnings last quarter?

Vermillion, Inc. (NASDAQ:VRML) announced its earnings results on Wednesday, August, 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.02. The firm earned $0.71 million during the quarter. Vermillion had a negative return on equity of 148.10% and a negative net margin of 778.21%.

When will Vermillion make its next earnings announcement?

Vermillion is scheduled to release their next quarterly earnings announcement on Monday, May, 15th 2017.

Where is Vermillion's stock going? Where will Vermillion's stock price be in 2017?

1 brokers have issued 1-year price targets for Vermillion's shares. Their forecasts range from $2.00 to $2.00. On average, they expect Vermillion's share price to reach $2.00 in the next twelve months.

Are investors shorting Vermillion?

Vermillion saw a drop in short interest in April. As of April 13th, there was short interest totalling 664,971 shares, a drop of 21.6% from the March 31st total of 848,628 shares. Based on an average daily volume of 64,523 shares, the short-interest ratio is presently 10.3 days. Approximately 1.9% of the shares of the stock are short sold.

Who owns Vermillion stock?

Vermillion's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Greenwich Wealth Management LLC (0.24%) and Essex Investment Management Co. LLC (0.16%). Company insiders that own Vermillion stock include Eric Schoen, Jack W Schuler, Larry N Feinberg, Valerie Barber Palmieri and Veronica Gh Jordan.

Who bought Vermillion stock? Who is buying Vermillion stock?

Vermillion's stock was acquired by a variety of institutional investors in the last quarter, including Greenwich Wealth Management LLC. Company insiders that have bought Vermillion stock in the last two years include Eric Schoen, Jack W Schuler, Larry N Feinberg, Valerie Barber Palmieri and Veronica Gh Jordan.

How do I buy Vermillion stock?

Shares of Vermillion can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Vermillion stock cost?

One share of Vermillion stock can currently be purchased for approximately $1.89.

Vermillion (VRML) Chart for Saturday, April, 29, 2017

This page was last updated on 4/29/2017 by Staff